Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis
- 1 September 2004
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 93 (3) , 243-248
- https://doi.org/10.1016/s1081-1206(10)61495-0
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthmaJournal of Allergy and Clinical Immunology, 2001
- Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitizationJournal of Allergy and Clinical Immunology, 2001
- Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitisJournal of Allergy and Clinical Immunology, 2000
- Treatment of Allergic Asthma with Monoclonal Anti-IgE AntibodyNew England Journal of Medicine, 1999
- Molecular Basis of Allergic DiseasesMolecular Genetics and Metabolism, 1998
- Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis☆☆☆★★★Journal of Allergy and Clinical Immunology, 1997
- Diesel exhaust particles induce local IgE production in vivo and alter the pattern of IgE messenger RNA isoforms.Journal of Clinical Investigation, 1994
- Rhinitis and asthmaJAMA, 1992
- Two unusual forms of human immunoglobulin E encoded by alternative RNA splicing of epsilon heavy chain membrane exons.The Journal of Experimental Medicine, 1992
- Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic responseJournal of Allergy and Clinical Immunology, 1988